This site is intended for healthcare professionals
CDK4/6 inhibitors in breast cancer

CME accredited module

Read time: 60 mins
Last updated:19th Jul 2021
Published:19th Jul 2021

Are you aware of the latest trends and studies on early breast cancer recurrence and risk stratification?

Take our interactive CME eLearning module to explore the evidence that supports the risk of recurrence in early breast cancer, treatment options available, methods being used for assessing the risk of recurrence and the clinical trial data on the three approved CDK4/6 inhibitors.

Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest